Overview
Overview
Products
News Overview
October 1, 2008
Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU
Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care » more
1:07 min.
Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU
Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care » more
1:48 min. 1:07 min.September 16, 2008
Venous Blood Clot Prevention after Elective Total Knee and Hip Replacement Surgery:
Bayer’s Xarelto® Approved in Canada
First approval for Bayer’s new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral, direct Factor Xa inhibitor in the world today » more
1:13 min.
Bayer’s Xarelto® Approved in Canada
First approval for Bayer’s new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral, direct Factor Xa inhibitor in the world today » more
1:13 min.September 12, 2008
Waterborne coating and adhesive raw materials now also from Shanghai:
Bayer MaterialScience expands global production network for polyurethane dispersions
Low-VOC raw materials for high-quality, environmentally friendly formulations » more
1:03 min.
Bayer MaterialScience expands global production network for polyurethane dispersions
Low-VOC raw materials for high-quality, environmentally friendly formulations » more
1:03 min.September 8, 2008
New low-dose oral contraceptive YAZ® launched in Europe
24/4 dosing regimen has shown to reduce hormone fluctuations » more
1:05 min.
24/4 dosing regimen has shown to reduce hormone fluctuations » more
1:05 min.September 4, 2008
Microstructured apparatus for the process industry
Novel, high-efficiency heat exchanger and reactor
Significantly greater heat transfer reduces apparatus and energy costs. Gentler on products » more
1:29 min.
Novel, high-efficiency heat exchanger and reactor
Significantly greater heat transfer reduces apparatus and energy costs. Gentler on products » more
1:29 min.September 2, 2008
Bayer Submits Recombinant Human Thrombin for European Approval
Recothrom® would be the first recombinant human thrombin for use as a topical aid to surgical hemostasis in Europe » more
1:01 min.
Recothrom® would be the first recombinant human thrombin for use as a topical aid to surgical hemostasis in Europe » more
1:01 min.July 30, 2008
Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.
Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues attributable to rivaroxaban after long-term exposure » more
1:23 min.
Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.
Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues attributable to rivaroxaban after long-term exposure » more
1:23 min.June 30, 2008
Venous Blood Clot Prevention after Knee and Hip Replacement Surgery:
Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death
Rivaroxaban shows superior efficacy to enoxaparin for this clinical outcome with a comparable safety profile / Pre-specified analysis of pooled data from RECORD 1-3 studies involving nearly 10,000 patients » more
Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death
Rivaroxaban shows superior efficacy to enoxaparin for this clinical outcome with a comparable safety profile / Pre-specified analysis of pooled data from RECORD 1-3 studies involving nearly 10,000 patients » more
June 24, 2008
Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United States
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer’s Women’s Healthcare Business Unit expected » more
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer’s Women’s Healthcare Business Unit expected » more
June 12, 2008
June 2, 2008
May 30, 2008
Prevention of Thromboembolism after Knee Replacement Surgery:
Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice-Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates / RECORD4 Confirms Results of RECORD1, 2 and 3 / U.S. Submission Planned for mid 2008 / Prof. Turpie: “Rivaroxaban has the potential to revolutionize the way we prevent the formation of dangerous blood clots” » more
1:46 min.
Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice-Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates / RECORD4 Confirms Results of RECORD1, 2 and 3 / U.S. Submission Planned for mid 2008 / Prof. Turpie: “Rivaroxaban has the potential to revolutionize the way we prevent the formation of dangerous blood clots” » more
1:46 min.May 29, 2008
UEFA EURO 2008™:
Soccer ball with goose bumps
New surface structure of the “EUROPASS” was realized with Impranil® » more
Soccer ball with goose bumps
New surface structure of the “EUROPASS” was realized with Impranil® » more
May 29, 2008
Collaboration with adidas
Bayer MaterialScience sets the ball rolling
The high-performance Impranil® coating takes the lead again at the European Championship » more
Bayer MaterialScience sets the ball rolling
The high-performance Impranil® coating takes the lead again at the European Championship » more
May 26, 2008
Bayer MaterialScience works on materials for robotics
Tidy up? My robot’s done it already!
The wrinkle-free polyurethane skin for service robots » more
Tidy up? My robot’s done it already!
The wrinkle-free polyurethane skin for service robots » more
May 6, 2008
April 30, 2008
New production process for natural oil polyols for rigid polyurethane foams
Optimized utilization of renewable raw materials
Promising potential for rigid thermal insulation applications » more
Optimized utilization of renewable raw materials
Promising potential for rigid thermal insulation applications » more
April 16, 2008
Patent infringement lawsuit against Chinese supplier:
Bayer CropScience to enforce its Mefenpyr patent
Intellectual property (IP) rights are the basis for innovation » more
Bayer CropScience to enforce its Mefenpyr patent
Intellectual property (IP) rights are the basis for innovation » more
April 15, 2008
Study on sandwich structures in the construction sector
Translucent design elements for interiors
» more
Translucent design elements for interiors
» more
more News
Bookmark this page
E-mail this page
Press Newsletter
